GlassScriptPhysician profile
Marvin W Johnson
NPI 1346244092
$3,927.88
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,467 · 2020: $1,550 · 2021: $911.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $418.25 | 2019-2020 | |
| Amgen INC. | $348.11 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $314.88 | 2019-2021 | |
| Radius Health, INC. | $269.52 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.62 | 2019-2021 | |
| Lilly USA, LLC | $250.15 | 2019-2021 | |
| Horizon Therapeutics Plc | $233.91 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $223.67 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $207.14 | 2019-2021 | |
| Abbvie INC. | $179.77 | 2021 | |
| Janssen Pharmaceuticals, INC | $172.52 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $152.91 | 2021 | |
| Merck Sharp & Dohme LLC | $152.40 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $148.58 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $101.10 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $90.36 | 2019-2020 | |
| Pfizer INC. | $78.00 | 2019-2020 | |
| Mylan Specialty L.P. | $52.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $48.80 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $48.00 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.30 | 2019-2021 | |
| Astellas Pharma US INC | $39.13 | 2019 | |
| Hikma Pharmaceuticals USA | $36.83 | 2020 | |
| Amarin Pharma, INC. | $30.03 | 2020 | |
| Novo Nordisk INC | $18.19 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $17.71 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.